Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H23NO3.C10H16O4S |
Molecular Weight | 545.687 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.[H][C@@]34OC5=C(OCC)C=CC6=C5[C@@]37CCN(C)[C@H](C6)[C@]7([H])C=C[C@@H]4O
InChI
InChIKey=NKOFCJOTATYGHA-LAZTUONISA-N
InChI=1S/C19H23NO3.C10H16O4S/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h4-7,12-14,18,21H,3,8-10H2,1-2H3;7H,3-6H2,1-2H3,(H,12,13,14)/t12-,13+,14-,18-,19-;7-,10-/m01/s1
Molecular Formula | C10H16O4S |
Molecular Weight | 232.297 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C19H23NO3 |
Molecular Weight | 313.3908 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
CNS Activity
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.09 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
222 μM × min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
8.5 mg single, oral |
healthy, 10 months n = 1 Health Status: healthy Age Group: 10 months Sex: M Population Size: 1 Sources: |
Other AEs: Sedation... |
1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years n = 10 Health Status: healthy Age Group: 24 years Sex: M Population Size: 10 Sources: |
Other AEs: Dizziness, Drowsiness... Other AEs: Dizziness (7 patients) Sources: Drowsiness (slight, 2 patients) Loose stools (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sedation | grade 5 | 8.5 mg single, oral |
healthy, 10 months n = 1 Health Status: healthy Age Group: 10 months Sex: M Population Size: 1 Sources: |
Loose stools | 1 patient | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years n = 10 Health Status: healthy Age Group: 24 years Sex: M Population Size: 10 Sources: |
Dizziness | 7 patients | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years n = 10 Health Status: healthy Age Group: 24 years Sex: M Population Size: 10 Sources: |
Drowsiness | slight, 2 patients | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years n = 10 Health Status: healthy Age Group: 24 years Sex: M Population Size: 10 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous determination of codeine and ethyl morphine HCL in tablet formulations using LC. | 2001 Aug |
|
[Experimental study on using diclofenac sodium or dionine topically to treat fibrinous membrane after intraocular lens implantation]. | 2001 Jun 28 |
|
Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors. | 2003 Sep |
|
Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens. | 2004 Jul 16 |
|
Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms. | 2005 Jan |
|
Automated multiple development thin-layer chromatography for separation of opiate alkaloids and derivatives. | 2005 Jul 8 |
|
Electrospray LC-MS method with solid-phase extraction for accurate determination of morphine-, codeine-, and ethylmorphine-glucuronides and 6-acetylmorphine in urine. | 2007 Mar |
|
Purification of CYP2B-like protein from feral leaping mullet (Liza saliens) liver microsomes and its biocatalytic, molecular, and immunological characterization. | 2008 Jul-Aug |
|
Determining plasma morphine levels using GC-MS after solid phase extraction to monitor drug levels in the postoperative period. | 2008 Jun |
|
Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood. | 2008 May |
|
Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC-MS/MS. | 2009 Feb 1 |
|
Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays. | 2009 May |
|
[Pharmacological treatment of acute cough]. | 2009 May 14 |
|
[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value]. | 2009 Nov 4-12 |
|
Characterization of xenobiotic metabolizing enzymes in bovine small intestinal mucosa. | 2010 Jun 1 |
|
Death of a 10-month-old boy after exposure to ethylmorphine. | 2010 Mar 1 |
Sample Use Guides
The recommended dose in adults is 50 mg of codethyline per day, i.e. 10 tablets (1 tablet contains 5 mg of ethylmorphine hydrochloride) per day over several intakes, at a minimum of 4 hours apart. In children the normal dose is 1 tablet per intake, to be renewed after 6 hours if necessary, without exceeding 4 tablets per day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:07:06 UTC 2023
by
admin
on
Sat Dec 16 11:07:06 UTC 2023
|
Record UNII |
RX4SJ3L382
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RX4SJ3L382
Created by
admin on Sat Dec 16 11:07:06 UTC 2023 , Edited by admin on Sat Dec 16 11:07:06 UTC 2023
|
PRIMARY | |||
|
279-118-1
Created by
admin on Sat Dec 16 11:07:06 UTC 2023 , Edited by admin on Sat Dec 16 11:07:06 UTC 2023
|
PRIMARY | |||
|
91808966
Created by
admin on Sat Dec 16 11:07:06 UTC 2023 , Edited by admin on Sat Dec 16 11:07:06 UTC 2023
|
PRIMARY | |||
|
100000088240
Created by
admin on Sat Dec 16 11:07:06 UTC 2023 , Edited by admin on Sat Dec 16 11:07:06 UTC 2023
|
PRIMARY | |||
|
79241-89-7
Created by
admin on Sat Dec 16 11:07:06 UTC 2023 , Edited by admin on Sat Dec 16 11:07:06 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|